Investor Profile: Johnson & Johnson Innovation — Thesis, Cheque Size & How to Apply

Johnson & Johnson Innovation (JJDC) is the venture investment arm of Johnson & Johnson, and Johnson & Johnson Innovation funding gives founders a strategic backer spanning pharmaceuticals, medical devices and consumer health. JJDC invests through Johnson & Johnson Innovation, the group's early-stage innovation organisation, alongside its regional Innovation Centres, JLABS incubators and business development teams.

Investment thesis

JJDC's stated commitment goes beyond investment: it seeks early-stage companies whose science can solve unmet patient needs and that can benefit from a relationship with Johnson & Johnson's global healthcare businesses. Its 2025 focus areas are Oncology, Immunology and Neuroscience, with additional work in ophthalmology and platform technologies, from antibody engineering and degraders to cell and gene therapy manufacturing.

Sectors and stages

JJDC invests in early-stage life science companies, largely at preclinical through early clinical stages, and it also runs a new company creation effort that builds companies from scratch. Its 2025 private investments span oncology programmes such as radiotherapeutics and bispecific antibodies, immunology programmes in tissue-targeted genetic therapies and inflammation resolution, neuroscience programmes in gene delivery and neurodegeneration, and platform companies in AI-enabled cancer testing and cell therapy manufacturing.

Fund size and cheque size

JJDC's fund size and typical cheque size are not publicly disclosed in the sources we read. As a corporate venture arm funded from Johnson & Johnson's balance sheet rather than a closed-end fund, it does not publish a fund total, and founders should not assume a standard cheque: deal sizes vary by stage and syndicate.

Notable portfolio

Companies named in JJDC's 2025 investment materials include Abdera Therapeutics, PAQ Therapeutics, Accent Therapeutics, Rondo Therapeutics, Stylus Medicine, Aro Biotherapeutics, Mestag Therapeutics, SonoThera, AviadoBio, Perceive Bio and ArteraAI. Its 2025 portfolio M&A highlights listed in the same materials include transactions involving Datavant (undisclosed terms), a $2.1 billion AbbVie transaction and an $81.25 million Tempus transaction. Longer-standing portfolio names tracked by third-party databases include Carbon, CVRx, NeuroPace, Inspire Medical and BiomX.

Partners and team

Chris Picariello is President of JJDC, based in New Brunswick, New Jersey. The biotech investment team also includes principals and vice presidents across the Netherlands, London, Cambridge (Massachusetts) and San Francisco, plus a dedicated new company creation team, reflecting JJDC's global footprint.

Programmes and perks

JJDC sits alongside two genuine founder programmes. JLABS provides laboratories, expertise, education, tools and resources to help life science startups thrive, described by Johnson & Johnson Innovation as having "no strings attached", and all JLABS locations accept applications. QuickFire Challenges are Johnson & Johnson Innovation's online competitions through which innovators can submit ideas for funding and support.

How to apply for funding

JJDC does not publish an open rolling application form for venture cheques on the materials we read. Founders should engage through the Johnson & Johnson Innovation website: apply to JLABS for lab space and support, enter a QuickFire Challenge when a relevant call is open, or approach the JJDC team via the Johnson & Johnson Innovation partnering channels. A warm introduction from a syndicate investor or a JLABS relationship is the most common route into a JJDC conversation.